Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 53
- Registration Number
- NCT02782845
A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT02780622
A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2016-08-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 264
- Registration Number
- NCT02774278
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT02768207
- Locations
- 🇧🇪
UZ Brussel, Brussel, Belgium
🇧🇪UZ Antwerpen, Edegem, Belgium
🇧🇪Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
- Conditions
- Anemia
- Interventions
- Drug: r-HuEPO
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 61
- Registration Number
- NCT02767765
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 503
- Registration Number
- NCT02763579
- Locations
- 🇺🇸
Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States
🇺🇸Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, United States
🇺🇸Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States
Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)
- Conditions
- HIV/HCV Coinfection
- Interventions
- Drug: Peginterferon Alfa-2
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT02762383
A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Other: eBC treated participants
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT02761616
- Locations
- 🇦🇷
Cemic; Oncologia Clinica, Buenos Aires, Argentina
🇦🇷Hospital de Morón, Moron, Argentina
🇦🇷CENICLAR, Rosario, Argentina
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT02761642
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Peg-Interferon Alpha-2A
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 180
- Registration Number
- NCT02761629